PF-3845 is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), an enzyme responsible for the breakdown of endocannabinoids such as anandamide. By inhibiting FAAH, PF-3845 increases the levels of endogenous cannabinoids in the brain and peripheral tissues, which modulates pain perception, inflammation, and mood. It is widely used in preclinical research to study the endocannabinoid system, particularly in models of pain, anxiety, and neurodegenerative disorders. Due to its ability to enhance cannabinoid signaling without directly activating cannabinoid receptors, PF-3845 serves as a valuable tool for investigating therapeutic strategies for conditions involving chronic pain and inflammation, with potential applications in developing non-psychoactive analgesic and anxiolytic agents.